Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor—Darolutamide

Darolutamide is a next-generation androgen receptor signaling inhibitor (ARSI) currently approved for the treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone sensitive prostate cancer (mHSPC). Studies suggest that darolutamide also has the potential to be...

Descripción completa

Detalles Bibliográficos
Autores principales: Podgoršek, Eva, Mehra, Niven, van Oort, Inge M., Somford, Diederik M., Boerrigter, Emmy, van Erp, Nielka P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386912/
https://www.ncbi.nlm.nih.gov/pubmed/37458966
http://dx.doi.org/10.1007/s40262-023-01268-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386912/
https://www.ncbi.nlm.nih.gov/pubmed/37458966
http://dx.doi.org/10.1007/s40262-023-01268-w

Ejemplares similares